Topics

Companies Related to "Evaluating Safety Immunotherapy NSCLC Patients With Comorbidities" [Most Relevant Company Matches] RSS

14:34 EDT 4th April 2020 | BioPortfolio

Here are the most relevant search results for "Evaluating Safety Immunotherapy NSCLC Patients With Comorbidities" found in our extensive corporate database of over 50,000 company records.

Showing "Evaluating Safety Immunotherapy NSCLC Patients With Comorbidities" Companies 1–25 of 5,500+

Relevant

Outcomes Pharmaceutical Health Care

Outcome is the leading provider of patient registries, studies, quality improvement programs, and integrated technologies for evaluating real-world outcomes. Outcome provides services and technologies focused on evaluating the safety, effectiveness, and quality of healthcare products and services. The company has designed, developed, and managed an industr...


Biothera Pharmaceuticals Inc.

Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a first-in-class, mid-clinical stage cancer immunotherapy that orchestrates an integrated anti-cancer immune response in combination with checkpoint inhibitors and tumor-targeting and anti-angiogenesis monoclonal antibodies. Imprime PGG has been well-tolerated in tri...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...


Genosco

Located in Cambridge, MA, Genosco is a clinical-stage biotechnology company led by CEO, Dr. Jong Sung (John) Koh, focusing on developing and commercializing novel immunology and oncology treatments to improve the lives of patients. Genosco’s core competence comes from its expertise in generating selective kinase inhibitors that include candidates that ...

Outcome Sciences, Inc.

Outcome is the leading provider of patient registries, studies, quality improvement programs, and integrated technologies for evaluating real-world outcomes. Outcome provides services and technologies focused on evaluating the safety, effectiveness, and quality of healthcare products and services. The company has designed, developed, and managed more than ...

Biotech Synergy

Biotech Synergy has secured in San Diego the necessary competences to bring this promising multi epitope cancer vaccine to latest stage development. Contrary to Dendreon individualized vaccine, EP-2101 is made of 10 peptides and is an off the shelf readily available vaccine for the HLA-A2 population, which represents 45% of the global NSCLC patients (100,0...

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

Imposter Research

IMPOSTER is the name of a medical research study of patients with muscle symptoms while taking cholesterol lowering therapies called statins. Several important findings from this study have been published and have raised questions about the safety of statin therapy for patients with muscle complaints. This website was developed to address those questions and to share what is known about statin mu...

Biothera Pharmaceuticals, Inc.

Biothera is a privately held biotechnology company developing Imprime PGG, a clinical stage immunotherapy drug that modulates key immune cells to orchestrate a coordinated immune response to cancer that involves both the innate and adaptive immune system. Proof of concept has been established from single-arm and randomized phase 2 studies in non-small cell...

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

CARMA Therapeutics Inc.

CARMA TherapeuticsSM is a biotechnology company founded in 2016 to bring the power of adoptive cellular immunotherapy to solid tumor patients through a novel platform using chimeric antigen receptor macrophages (CARMA). The company’s proprietary technology was developed at the Center for Cellular Immunotherapy at the Perelman School of Medicine at the...

United Allergy Services

United Allergy Services™ (UAS) brings effective and convenient allergy testing and immunotherapy to primary care physicians; pulmonologists; ENT physicians; pediatricians; internal medicine physicians; and healthcare systems that treat the vast majority of patients with seasonal and perennial allergies. UAS’ complete service line features ...

Infinity Pharmaceuticals Inc.

Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, controlled combination study of IPI-549 combined with Opdivo in I/O naïve urothelial c...

Chiasma (Israel), LTD

Chiasma develops new drug products based on its proprietary Transient Permeability Enhancer (TPE) technology, which enables oral delivery of macromolecules (up-to 20 kDa) and poorly-absorbed small molecules into the GI wall, portal system and then to the systemic circulation. Chiasma creates its internal pipeline by selecting approved macromolecules that are currently available in injectable form...

Immunomic Therapeutics, Inc. and ZENOAQ

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. ITI has entered into a significant licensing agreement with ...

NextCure, Inc.

NextCure is a biopharmaceutical company focused on discovering and developing next generation first-in-class immunotherapy-based biologics for cancer and other diseases. The company leverages its FIND-IOTM technology to discover, validate and build a proprietary pipeline of novel immunotherapy targets.

The National Patient Safety Foundation

The National Patient Safety Foundation (NPSF) has been pursuing one mission since its founding in 1997 - to improve the safety of care provided to patients. As a central voice for patient safety, NPSF is committed to a collaborative, inclusive, multi-stakeholder approach in all that it does. NPSF is an independent, not-for-profit 501(c)(3) organization. To learn more about the work of the National...

Genitope

Genitope Corporation is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Immunotherapy products are designed to utilize the immune system to combat diseases such as cancer. Our lead product candidate, MyVax® Personalized Immunotherapy (previously referred to as GTOP-99) is currently in a pivotal Phase 3 trial for the treatment o...

Tennessee Center for Patient Safety

The mission of the Tennessee Center for Patient Safety is to advance Tennessee hospitals’ adoption of proven strategies that enhance the reliability, safety and quality of care received by patients. Established in 2007, the Tennessee Center for Patient Safety primarily is funded by the BlueCross BlueShield of Tennessee Health Foundation and operated b...

Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc. is a privately held biopharmaceutical company focused on applying a novel, small molecule immunotherapy platform to treat severe fungal infections in immune-compromised patients. Cidara recently announced that it has completed a $32 million Series A financing that will enable it to advance candidates from the company’s Cloudb...

ChanTest Inc.

To provideNon-Clinical drug safety testing and discovery services that accelerate drug development by:Leveraging our extensive experience in evaluating drug-induced effects on ion channels, purkinje fibers, and iolated hearts; Providing accurate, repeatable results; Consistently responding with a high sense of urgency

institut merieux

With extensive experience in industrial microbiology, Institut Merieux contributes to serving medicine and public health across the globe. For the fight against infectious diseases and cancer, it imagines and develops new approaches in the fields of diagnostics, immunotherapy, and food safety and nutrition.

Androclus Therapeutics

Androclus Therapeutics is a clinical-stage biotechnology company developing first-in-class selective therapeutics for the treatment of autoimmune diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and inflammatory bowel disease (IBD), based on a proprietary epitope-specific immunotherapy technology platform. The breakthrough technology platform has a potential of producing the ...

Cellerant Therapeutics Inc.

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant’s lead product, CLT-008 is currently in Phase 1 clinical trials evaluating safety in pa...

OncoGenex Technologies Inc.

OncoGenex Technologies Inc. (OncoGenex) is a clinical-stage biotechnology company dedicated to improving survival and quality of life of cancer patients by developing targeted therapeutics for treatment-resistant and metastatic cancer. The company's lead drug candidate, OGX-011, has commenced Phase 2 studies in prostate cancer (2), NSCLC and breast cancer. OGX-427 is in preclinical development and...


More From BioPortfolio on "Evaluating Safety Immunotherapy NSCLC Patients With Comorbidities"

Quick Search

Corporate Database Quicklinks